Lisata Therapeutics wins US method-of-use patent for certepetide in pancreatic cancer, solid tumors

• Lisata Therapeutics won a new US method-of-use patent for certepetide covering combination treatment of pancreatic cancer and other solid tumors.
• The patent expires in May 2041.
• Management said the grant supports market exclusivity into November 2043.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9841700) on October 08, 2026, and is solely responsible for the information contained therein.